THE Therapeutic Goods Administration has published Australian Public Assessment Reports (AusPARs) this month for MSD's hepatitis C therapy, new chemical entity Zepatier (grazoprevir/elbasvir) and for Gilead's HIV treatment Stribild (tenofovir disoproxil fumarate/emtricitabine/ elvitegravir/cobicistat) - see tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Jun 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Jun 17
